We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byΖεφύρα Παπαφιλίππου
Modified over 5 years ago
T-Cell Directed Therapy in MS
T Cells and B Cells in MS
T-Cell Directed Therapies: Alemtuzumab and Cladribine
T-Cell Directed Therapies: Daclizumab
T-Cell Directed Therapies: Fingolimod
T-Cell Directed Therapies: Natalizumab
T-Cell Directed Therapies: DMF
Evolution of Outcome Measures in MS
Evolution of NEDA in MS[a]
Practical Considerations in Implementing NEDA in Clinical Practice
NEDA as an Endpoint: Single-Center Data
NEDA as an Endpoint: Single-Center Data (cont)
NEDA as an Endpoint: Clinical Trial Data
Achieving NEDA With Cladribine: CLARITY
Achieving NEDA With Alemtuzumab: CARE-MS
Achieving NEDA With Daclizumab: DECIDE
Achieving DAF With Natalizumab: AFFIRM
Achieving NEDA With DMF: DEFINE/CONFIRM
Achieving NEDA-3 and NEDA-4 With Fingolimod: TRANSFORMS
Challenge of Implementing NEDA-4 in Clinical Practice
Achieving NEDA With Fingolimod: Real-World Data
Benefit/Risk Assessment in Targeting NEDA
Reversible Lymphocyte Redistribution With Fingolimod
Lymphopenia in Patients Treated With DMF
Lymphopenia in Patients Treated With Alemtuzumab or Cladribine
Setting Lymphocyte Count Thresholds in Clinical Practice
Treating to NEDA in Clinical Practice
Upfront Combination Therapy vs Step-Up Approach for PAH:
Multiple sclerosis: Oral Therapies and Beyond
The Patient Experience With Systemic Lupus Erythematosus
Immune Depletion, Immune Modulation, and Immunosuppression in MS: A Review.
Diabetic Dyslipidemia in Practice
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Highlights From the 2015 European Multiple Sclerosis Meeting
Highlights From the 2017 Annual European MS Meeting
Perspectives on Key MS Data From the Annual European MS Meeting
Program Goals Teriflunomide: Pooled Safety Data.
Statin Selection Aimed to Reduce New-Onset DM Risk:
Immune Reconstitution in MS:
What Predicts Disability Progression in Multiple Sclerosis?
Current Controversies in Multiple Sclerosis Management
Applying Real-World Evidence in MS: Reviewing the State of the Art
The HCV Revolution: Are You and Your Practice Ready?
Perspectives on Key MS Data From the Annual Neurology Meeting
Metastatic Renal Cell Carcinoma
What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?
Obesity and Dyslipidemia: How Would You Treat?
© 2023 SlidePlayer.com Inc. All rights reserved.